Sep 3, 2025 8:00 am EDT Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aug 27, 2025 8:00 am EDT Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
Aug 18, 2025 8:00 am EDT Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
Aug 13, 2025 4:30 pm EDT Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
Aug 5, 2025 8:00 am EDT Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Jul 23, 2025 8:00 am EDT Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
Jul 3, 2025 4:30 pm EDT Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 26, 2025 6:55 am EDT Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Jun 23, 2025 8:00 am EDT Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program